New targets for heart-failure therapy: Endothelin, inflammatory cytokines, and oxidative stress

Lancet

Volumn 352, Issue SUPPL.1, 1998, Pages 34-38

  Givertz, Michael M ^b   Colucci, Wilson S ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENDOTHELIN;

HEART FAILURE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0031706081     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(98)90017-4     Document Type: Article

References (75)

1. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997; 80: 15L-25L.
2. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997; 349: 747-52.
3. Swedberg K, Waagstein F, Dickstein K, Wiltse C, McNay J. Moxonidine, a centrally acting sympathetic inhibitor, causes sustained reduction in plasma norepinephrine in heart failure patients. J Am Coll Cardiol 1997; 29: 220A.
4. Oz MC, Argenciano M, Catanese KA, et al. Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? Circulation 1997; 95: 1844-52.
5. Colucci WS. Myocardial endothelin. Does it play a role in myocardial failure? Circulation 1996; 93: 1069-72.
6. Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265: 20555-62.
7. Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96: 4065-82.
8. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-09.
9. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-86.
10. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995; 75: 1282-83.
11. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94: 1578-84.
12. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ. Pulmonary and systemic responses to exogenous endothelin-1 in patients with left ventricular dysfuntion. J Cardiovasc Pharmacol 1998; 31 (suppl 1): S290-3.
13. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 1997; 96: 1976-82.
14. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 1997; 96: 3963-73.
15. Sakai S, Miyauchi T, Sakurai T, et al. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure: marked increase in endothelin-1 production in the failing heart. Circulation 1996; 93: 1214-22.
16. Sakai S, Miyauchi T, KobayashM, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-55.
17. Kiowski W, Sutsch G, Hunziker P, et al. Evidence of endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-36.
18. Sutsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997; 10: 717-25.
19. Wu C. Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997; 40: 1690-97.
20. Investigators' Brochure. West Point, PA: Merck & Co, Inc, 1997.
21. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-85.
22. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
23. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996; 27: 1201-06.
24. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
25. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996; 347: 1151-55.
26. de Beider AJ, Radomski MW, Why HJ, et al. Nitric oxide synthase activities in human myocardium. Lancet 1993; 341: 84-85.
27. Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1087-94.
28. Hare JM, Colucci WS. Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 1995; 38: 155-66.
29. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-77.
30. Okura Y, Yamamoto T, Goto S, et al. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 1997; 29: 491-502.
31. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure. Potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998; 97: 161-66.
32. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995; 95: 677-85.
33. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98: 2854-65.
34. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995; 96: 1093-99.
35. Calderone A, Thaik CM, Takahashi N, Chang DLF, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cGMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998; 101: 812-18.
36. Sciavolini PJ, Lee TH, Vilcek J. Interferon-beta induces metalloproteinase mRNA expression in human fibroblasts: role of activator protein-1. J Biol Chem 1994; 269: 21627-34.
37. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997; 81: 627-35.
38. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97: 1375-81.
39. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382-91.
40. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
41. Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 1996; 335: 311-15.
42. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-47.
43. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-702.
44. Deswal A, Seta Y, Blosch CM, Mann DL. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure. Circulation 1997; 96: I-323.
45. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-36.
46. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989; ii: 1474-77.
47. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995; 22: 625-29.
48. Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-68.
49. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998; 351: 1091-93.
50. Clift RA, Bianco JA, Appelbaum FR, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025-30.
51. Wagner DR, McTiernan C, Sanders VJ, Feldman AM. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 1998; 97: 521-24.
52. McMurray J, McLay J, Chopra M, Bridges A, Belch JJ. Evidence for enhanced free-radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990; 65: 1261-62.
53. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993; 14: 1493-98.
54. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996; 131: 146-52.
55. Keith M, Geranmayegan A, Sole MJ, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31: 1352-56.
56. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 97: 1536-39.
57. Dhalla AK, Singal PK. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am J Physiol 1994; 266: H1280-85.
58. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol 1996; 148: 291-300.
59. Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995; 96: 2247-59.
60. Boota A, Zar H, Kim YM, Johnson B, Pitt B, Davies P. IL-1 beta stimulates superoxide and delayed peroxynitrite production by pulmonary vascular smooth muscle cells. Am J Physiol 1996; 271: L932-36.
61. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159-63.
62. Goldhaber JI. Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. Am J Physiol 1996; 271: H823-33.
63. Lopez BL, Liu GL, Christopher TA, Ma XL. Peroxynitrite, the product of nitric oxide and superoxide, causes myocardial injury in the isolated perfused rat heart. Coron Artery Dis 1997; 8: 149-53.
64. Tzortzis JD, Siwik DA, Chang DL, et al. Chronic oxidative stress induces a hypertrophie phenotype and apoptosis in neonatal rat cardiac myocytes in vitro. Circulation 1997; 96: I-605.
65. Lebovitz RM, Zhang H, Vogel H, et al Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA 1996; 93: 9782-87.
66. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28: 506-14.
67. Ghatak A, Brar MJ, Agarwal A, et al. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Int J Cardiol 1996; 57: 119-27.
68. Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1990; 65: 521-23.
69. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA 1985; 82: 4240-44.
70. Morisco C, Trimarco B, Condoreili M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Invest 1993; 71: S134-36.
71. Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklung I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Fail 1995; 1: 101-07.
72. Permanetter B, Rossy W, Klein G, Weingartner F, Seidl KF, Blomer H. Ubiquinone (coenzyme Q10) in the long-term treatment of idopathic dilated cardiomyopathy. Eur Heart J 1992; 13: 1528-33.
73. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-98.
74. Kukin ML, Kalman J, Charney RH, et al. Antioxidant effect of carvedilol and metoprolol in congestive heart failure. J Am Coll Cardiol 1998; 31: 189A.
75. Suzuki S, Sato H, Shimada H, Takashima N, Arakawa M. Comparative free radical scavenging action of angiotensin-converting enzyme inhibitors with and without the sulfhydryl radical. Pharmacology 1993; 47: 61-65.